-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 8, according to the official website of CDE, Haisco Pharmaceuticals applied for the listing of the 3 generic ranolazine sustained-release tablets (acceptance number: CYHS2101986/7)
Source: CDE official website
Ranolazine was developed by Gilead and is the first drug approved by the FDA for the treatment of chronic angina pectoris in the past decade.
According to the Insight database, ranolazine global sales reached a peak of US$758 million in 2018.
Ranolazine global sales
Source: Insight database (http://db.
Ranolazine has not yet been marketed in China.
Ranolazine variety competition details (Insight)
Source: Insight database (http://db.